Livzon Pharmaceutical Group Inc Class H (HK:1513)
:1513
Want to see HK:1513 full AI Analyst Report?
Top Page
Livzon Pharmaceutical Group
(1513)
Select Model
Select Model
Rating:72Outperform
Price Target:
HK$31.00
â–²(0.19% Upside)
Action:ReiteratedDate:04/24/26
The score is driven primarily by strong financial quality (healthy margins, conservative leverage, solid free cash flow) and supportive valuation with a high dividend yield. These positives are tempered by weak-to-neutral technical positioning (below longer-term moving averages) and ongoing revenue decline, which remains the key fundamental risk.
Positive Factors
Profitability margins
High and consistent gross, EBIT and net margins (~65%, ~22%, ~17%) indicate durable pricing power and efficient manufacturing. Over 2–6 months this supports steady cash earnings, resilience versus pricing pressure in generics/specialty pharma, and a reliable earnings base for reinvestment.
Negative Factors
Revenue decline
A multi-year top-line decline (TTM -2.8%) signals weakening demand, pricing pressure or share loss. Sustained revenue contraction limits scale benefits, constrains reinvestment capacity and makes it harder to offset fixed costs, risking margin erosion and slower long-term growth absent a clear recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability margins
High and consistent gross, EBIT and net margins (~65%, ~22%, ~17%) indicate durable pricing power and efficient manufacturing. Over 2–6 months this supports steady cash earnings, resilience versus pricing pressure in generics/specialty pharma, and a reliable earnings base for reinvestment.
Read all positive factors
Livzon Pharmaceutical Group (1513) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$30.61B
Dividend Yield4.09%
Average Volume (3M)553.85K
Price to Earnings (P/E)9.4
Beta (1Y)0.72
Revenue Growth1.48%
EPS Growth-1.55%
CountryHK
Employees9,067
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.75
Shares Outstanding299,807,130
10 Day Avg. Volume697,200
30 Day Avg. Volume553,853
Financial Highlights & Ratios
PEG Ratio-8.67
Price to Book (P/B)1.65
Price to Sales (P/S)1.97
P/FCF Ratio9.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$31.00Price Target Upside0.18% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)2.37
Revenue Forecast (FY)HK$12.28B
Livzon Pharmaceutical Group Business Overview & Revenue Model
Company Description
Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteri...
How the Company Makes Money
null...
Livzon Pharmaceutical Group Financial Statement Overview
Summary
Income Statement
77
Positive
Balance Sheet
82
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.64B | 11.60B | 11.81B | 12.43B | 12.63B | 12.06B |
| Gross Profit | 7.66B | 7.43B | 7.73B | 7.66B | 8.17B | 7.81B |
| EBITDA | 2.87B | 3.10B | 3.47B | 3.33B | 3.08B | 2.77B |
| Net Income | 1.95B | 1.97B | 2.06B | 1.95B | 1.91B | 1.78B |
Balance Sheet | ||||||
| Total Assets | 24.11B | 24.00B | 24.46B | 25.04B | 24.86B | 22.37B |
| Cash, Cash Equivalents and Short-Term Investments | 9.56B | 10.93B | 10.92B | 11.41B | 10.52B | 9.33B |
| Total Debt | 2.89B | 3.85B | 3.93B | 3.48B | 3.62B | 2.69B |
| Total Liabilities | 8.58B | 8.20B | 9.55B | 10.28B | 9.93B | 8.06B |
| Stockholders Equity | 14.46B | 13.89B | 13.86B | 14.04B | 13.88B | 13.00B |
Cash Flow | ||||||
| Free Cash Flow | 2.75B | 2.54B | 2.41B | 2.43B | 1.83B | 593.23M |
| Operating Cash Flow | 3.28B | 3.10B | 2.98B | 3.25B | 2.77B | 1.90B |
| Investing Cash Flow | -4.36B | -3.67B | -660.33M | -708.37M | -1.23B | -1.88B |
| Financing Cash Flow | -2.65B | -2.62B | -2.49B | -1.66B | -720.36M | -815.02M |
Livzon Pharmaceutical Group Technical Analysis
Positive
30.94
Price Trends
28.54
Positive
29.30
Negative
31.96
Negative
Market Momentum
0.25
Negative
54.75
Neutral
57.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1513, the sentiment is Positive. The current price of 30.94 is above the 20-day moving average (MA) of 28.03, above the 50-day MA of 28.54, and below the 200-day MA of 31.96, indicating a neutral trend. The MACD of 0.25 indicates Negative momentum. The RSI at 54.75 is Neutral, neither overbought nor oversold. The STOCH value of 57.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1513.
Livzon Pharmaceutical Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$23.29B | 22.15 | 7.26% | 3.13% | 5.48% | -49.67% | |
72 Outperform | HK$30.61B | 9.36 | 14.47% | 4.09% | 1.48% | -1.55% | |
71 Outperform | HK$19.43B | 9.66 | 12.63% | 5.11% | -4.09% | -25.02% | |
63 Neutral | HK$32.62B | 19.33 | 8.60% | 2.26% | 10.00% | -7.54% | |
61 Neutral | HK$36.31B | 6.37 | 7.91% | 2.95% | 4.66% | 20.77% | |
56 Neutral | HK$39.99B | 8.90 | 7.89% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1513
Livzon Pharmaceutical Group
28.20
3.25
13.02%
HK:3933
The United Laboratories International Holdings
9.54
-3.57
-27.23%
HK:0867
China Medical System Holdings
13.06
5.08
63.70%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
16.52
0.76
4.85%
HK:3320
China Resources Pharmaceutical Group Ltd.
5.29
0.50
10.48%
HK:0512
Grand Pharmaceutical Group Limited
6.34
0.38
6.38%
Livzon Pharmaceutical Group Corporate Events
Livzon Pharmaceutical Issues Revised Proxy Form for 2025 AGM
Apr 24, 2026
Livzon Pharmaceutical Group has issued a revised proxy form for its 2025 annual general meeting scheduled for 29 May 2026, replacing the original version solely to correct typographical and formatting issues without altering any substantive conten...
Livzon Pharmaceutical Updates 2025 Final Dividend Timetable and Tax Details
Apr 23, 2026
Livzon Pharmaceutical Group has updated details of its proposed final dividend for the financial year ended 31 December 2025, declaring a cash payout of RMB 14.3 per 10 shares subject to shareholder approval on 29 May 2026. The company clarified t...
Livzon Pharmaceutical Sets 2025 AGM to Approve Results and Cash Dividend Plan
Apr 23, 2026
Livzon Pharmaceutical Group has called its 2025 annual general meeting for 29 May 2026 in Zhuhai, combining on-site and online voting for shareholders. The agenda covers approval of the 2025 annual report, board work report and financial accounts,...
Livzon Seeks Mandate for 10% H-Share Buyback to Bolster Capital Flexibility
Apr 23, 2026
Livzon Pharmaceutical Group has convened its first 2026 class meeting of H shareholders to vote on a special resolution granting the board a general mandate to repurchase up to 10% of the company’s H shares. The proposed authorization would ...
Livzon Pharmaceutical’s First-Quarter Profit Slips as Policy Shift and Seasonality Hit Revenue
Apr 23, 2026
Livzon Pharmaceutical Group reported unaudited first-quarter 2026 results prepared under China Accounting Standards, showing operating income of RMB2.871 billion and net profit attributable to shareholders of RMB577 million. Operating income and n...
Livzon Reshapes Board Succession Plan With Nomination of Vice President Liu Daping
Apr 23, 2026
Livzon Pharmaceutical Group has adjusted its board succession plan by withdrawing an earlier proposal to appoint Vice President Liu Daping as an executive director in the 11th board session, instead nominating him for the 12th board session to ali...
Livzon Wins NMPA Nod for JP-1366 H. pylori Trial, Deepening GI Drug Portfolio
Apr 10, 2026
Livzon Pharmaceutical Group has received approval from China’s National Medical Products Administration to conduct clinical trials of its innovative JP-1366 tablet, a potassium-competitive acid blocker, in combination with antibiotics for th...
Livzon Pharmaceutical Schedules Board Meeting to Review First-Quarter 2026 Results
Apr 8, 2026
Livzon Pharmaceutical Group has scheduled a board meeting for 23 April 2026 to review and approve the unaudited quarterly results for the three months ended 31 March 2026, and to address any other business matters. The announcement underlines regu...
Livzon Clarifies 2025 Dividend Plan, Confirms RMB14.30 per 10 Shares
Mar 26, 2026
Livzon Pharmaceutical Group has issued a supplemental clarification to its previously announced 2025 profit distribution plan, correcting an earlier wording that could mislead investors about the size of the planned cash dividend. The company conf...
Livzon Wins NMPA Nod to Trial Long-Acting Brexpiprazole for Schizophrenia
Mar 26, 2026
Livzon Pharmaceutical Group’s subsidiary Zhuhai Livzon Microsphere Technology has received approval from China’s National Medical Products Administration to begin clinical trials of its independently developed Brexpiprazole Microsphere...
Livzon Pharmaceutical Strengthens Board Committees With New Appointments
Mar 24, 2026
Livzon Pharmaceutical Group has adjusted the composition of its board-level committees, reinforcing its corporate governance framework. The company appointed employee representative director Ms. Ran Yongmei to the Strategy Committee and executive ...
Livzon Pharmaceutical Outlines Board and Committee Structure
Mar 24, 2026
Livzon Pharmaceutical Group has disclosed the current composition of its board of directors and the membership of its five key board committees, reaffirming its corporate governance structure. The board comprises executive, non-executive, independ...
Livzon Pharmaceutical Proposes Final 2025 Dividend of RMB 14.3 per 10 Shares
Mar 24, 2026
Livzon Pharmaceutical Group Inc. has proposed a final ordinary cash dividend of RMB 14.3 per 10 shares for the financial year ended 31 December 2025, with the amount to be paid to Hong Kong shareholders to be translated into Hong Kong dollars at a...
Livzon Pharmaceutical Publishes Audited 2025 Results and Annual Report
Mar 24, 2026
Livzon Pharmaceutical Group announced its audited results for the year ended 31 December 2025, releasing the full 2025 Annual Report in compliance with Hong Kong listing requirements. The report, which includes management discussion, financial hig...
Livzon Pharmaceutical Cuts Registered Capital and Streamlines Board Structure
Mar 24, 2026
Livzon Pharmaceutical Group has updated its registered capital to RMB887,907,171 after changes in share capital arising from the exercise of share incentives and the cancellation of repurchased shares, resulting in 887,907,171 ordinary shares spli...
Livzon Wins Vietnam Approval for Tender Offer for Imexpharm Shares
Mar 6, 2026
Livzon Pharmaceutical Group has secured regulatory approval from the State Securities Commission of Vietnam for a voluntary public tender offer for shares in Imexpharm Corporation, a listed Vietnamese pharmaceutical company. The offer will be exec...
Livzon Pharmaceutical Sets March Board Meeting to Approve 2025 Annual Results
Mar 2, 2026
Livzon Pharmaceutical Group has scheduled a board meeting for 24 March 2026 to review and approve the audited annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider recommendi...
Livzon Pharmaceutical Announces Senior Leadership Reshuffle and Board Changes
Mar 1, 2026
Livzon Pharmaceutical Group announced that executive director and vice chairman Xu Guoxiang and non-executive director and vice chairman Tao Desheng have resigned upon reaching retirement age, relinquishing all roles in the group and its affiliate...
Livzon Pharmaceutical Group Details Board and Committee Structure
Mar 1, 2026
Livzon Pharmaceutical Group has detailed the current composition of its board of directors, naming executive, non-executive, employee representative and independent non-executive members, with Zhu Baoguo serving as chairman and Tang Yanggang as vi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.